Orly Haskin1,2, Yafa Falush3, Miriam Davidovits3,4. 1. Department of Pediatric Nephrolgy, Schneider Children's Medical Center of Israel, 14 Kaplan St., Petah Tikva, Israel. orly.haskin@gmail.com. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. orly.haskin@gmail.com. 3. Department of Pediatric Nephrolgy, Schneider Children's Medical Center of Israel, 14 Kaplan St., Petah Tikva, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. CASE-DIAGNOSIS/TREATMENT: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. CONCLUSION: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.
BACKGROUND:Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery. CASE-DIAGNOSIS/TREATMENT: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis. CONCLUSION: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.
Authors: Marjolein Bonthuis; Jérôme Harambat; Etienne Bérard; Karlien Cransberg; Ali Duzova; Liliana Garneata; Maria Herthelius; Adrian C Lungu; Timo Jahnukainen; Lukas Kaltenegger; Gema Ariceta; Elisabeth Maurer; Runolfur Palsson; Manish D Sinha; Sara Testa; Jaap W Groothoff; Kitty J Jager Journal: Clin J Am Soc Nephrol Date: 2018-09-20 Impact factor: 8.237
Authors: Larry A Greenbaum; Marc Fila; Gianluigi Ardissino; Samhar I Al-Akash; Jonathan Evans; Paul Henning; Kenneth V Lieberman; Silvio Maringhini; Lars Pape; Lesley Rees; Nicole C A J van de Kar; Johan Vande Walle; Masayo Ogawa; Camille L Bedrosian; Christoph Licht Journal: Kidney Int Date: 2016-01-28 Impact factor: 10.612
Authors: Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat Journal: Kidney Int Date: 2015-02-04 Impact factor: 10.612
Authors: Rafael Alonso Valente; Giannina Elena García Rodríguez; Yanina García Marcote; Manuel Fidalgo Díaz; Vanesa Becerra Mosquera; Daniel Novoa García; Teresa Cordal Martínez; Cándido Díaz Rodríguez Journal: Case Rep Nephrol Dial Date: 2017-03-02